|
CZ305838B6
(cs)
*
|
2001-03-29 |
2016-04-06 |
Eli Lilly And Company |
N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
|
|
EP1411925A1
(en)
*
|
2001-08-03 |
2004-04-28 |
PHARMACIA & UPJOHN COMPANY |
5-arylsulfonyl indoles having 5-ht6 receptor affinity
|
|
BR0312176A
(pt)
|
2002-06-21 |
2005-04-05 |
Suven Life Sciences Ltd |
Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
|
|
CN1297540C
(zh)
*
|
2002-07-17 |
2007-01-31 |
力奇制药公司 |
用作胆固醇生物合成抑制剂的吡啶基乙醇(苯乙基)胺的衍生物、它们的制备方法和含有它们的药物组合物
|
|
SI2208727T1
(sl)
|
2002-09-19 |
2012-11-30 |
Lilly Co Eli |
Diaril etri kot antagonisti opioidnega receptorja
|
|
CA2508290C
(en)
*
|
2002-12-20 |
2017-02-28 |
Ciba Specialty Chemicals Holding Inc. |
Synthesis of amines and intermediates for the synthesis thereof
|
|
EP1613597B1
(en)
|
2003-03-07 |
2007-11-07 |
Eli Lilly and Company |
6-substituted nicotinamide derivatives as opioid receptor antagonists
|
|
CN1753884A
(zh)
|
2003-03-07 |
2006-03-29 |
伊莱利利公司 |
阿片类受体拮抗剂
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
US8754238B2
(en)
|
2003-07-22 |
2014-06-17 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
ES2390459T3
(es)
|
2003-12-22 |
2012-11-13 |
Eli Lilly And Company |
Antagonistas de receptores de opioides
|
|
WO2005090286A1
(en)
|
2004-03-12 |
2005-09-29 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
CA2557794A1
(en)
|
2004-03-15 |
2005-10-06 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
CA2558030A1
(en)
|
2004-03-15 |
2005-09-29 |
Eli Lilly And Company |
4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
|
|
MX341797B
(es)
|
2004-06-24 |
2016-09-02 |
Vertex Pharmaceuticals Incorporated * |
Moduladores de transportadores con casete de union con atp.
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
NZ553646A
(en)
*
|
2004-09-22 |
2010-07-30 |
Janssen Pharmaceutica Nv |
Inhibitors of the interaction between MDM2 and p53
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
CN101351707B
(zh)
*
|
2005-12-28 |
2014-03-26 |
积水医疗株式会社 |
凝集测量用试剂以及凝集测量方法
|
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
UY30079A1
(es)
*
|
2006-01-06 |
2007-08-31 |
Astrazeneca Ab |
Compuestos
|
|
JP5385125B2
(ja)
*
|
2006-03-22 |
2014-01-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ＭＤＭ２とｐ５３の間の相互作用の阻害剤
|
|
AU2007228784B2
(en)
|
2006-03-22 |
2012-03-08 |
Janssen Pharmaceutica N.V. |
Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
|
|
EP2133337A1
(en)
|
2006-05-09 |
2009-12-16 |
AstraZeneca AB |
Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
PA8792401A1
(es)
|
2007-08-06 |
2009-03-31 |
Janssen Pharmaceutica Nv |
Fenilendiaminas
|
|
JO2704B1
(en)
*
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
EP2209380A4
(en)
*
|
2007-10-09 |
2011-09-14 |
Mark T Hamann |
METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
|
|
WO2009073118A1
(en)
|
2007-12-04 |
2009-06-11 |
Merck & Co., Inc. |
Tryptamine sulfonamides as 5-ht6 antagonists
|
|
US9084742B2
(en)
|
2007-12-12 |
2015-07-21 |
Axovant Sciences Ltd. |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
|
|
AU2009214724A1
(en)
*
|
2008-02-11 |
2009-08-20 |
Organix Inc. |
Indole compounds and methods of use thereof
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
AU2010210178B2
(en)
*
|
2009-02-04 |
2014-06-05 |
Janssen Pharmaceutica Nv |
Indole derivatives as anticancer agents
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
MX384179B
(es)
|
2009-03-20 |
2025-03-14 |
Vertex Pharma |
Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
|
|
EP2464227A4
(en)
*
|
2009-08-10 |
2013-02-20 |
Galenea Corp |
COMPOUNDS AND METHODS OF USE
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
*
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
薬学的組成物およびその投与
|
|
NZ629855A
(en)
|
2012-03-20 |
2016-01-29 |
Adamed Sp Zoo |
Sulphonamide derivatives of benzylamine for the treatment of cns diseases
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
|
US20160038484A1
(en)
*
|
2013-04-03 |
2016-02-11 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
*
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
EP3204358B1
(en)
|
2014-10-07 |
2018-09-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
US20160168089A1
(en)
|
2014-12-12 |
2016-06-16 |
H. Lundbeck A/S |
Process for the manufacture of idalopirdine
|
|
RU2017145976A
(ru)
|
2015-06-12 |
2019-07-15 |
Аксовант Сайенсиз Гмбх |
Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
|
|
TW201720439A
(zh)
|
2015-07-15 |
2017-06-16 |
Axovant Sciences Gmbh |
用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
|
|
WO2017067670A1
(en)
|
2015-10-23 |
2017-04-27 |
Pharmathen S.A. |
A novel process for the preparation of tryptamines and derivatives thereof
|
|
CN108884034A
(zh)
*
|
2016-04-08 |
2018-11-23 |
H.隆德贝克有限公司 |
经由亚胺的氢化制造艾达鲁吡啶的方法
|
|
ES2949288T3
(es)
|
2016-04-26 |
2023-09-27 |
H Lundbeck As |
Uso de un inhibidor de acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con enfermedad de Parkinson
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
SG11201909895UA
(en)
|
2017-05-24 |
2019-11-28 |
H Lundbeck As |
Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
|
|
AU2018358663B2
(en)
*
|
2017-11-06 |
2022-09-29 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to AB42 oligomer formation
|
|
CN113543852A
(zh)
|
2019-03-06 |
2021-10-22 |
第一三共株式会社 |
吡咯并吡唑衍生物
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
US11759452B2
(en)
|
2020-05-08 |
2023-09-19 |
Psilera Inc. |
Compositions of matter and pharmaceutical compositions
|
|
JP7766623B2
(ja)
|
2020-05-19 |
2025-11-10 |
サイビン アイアールエル リミテッド |
重水素化トリプタミン誘導体および使用方法
|
|
MX2023002619A
(es)
*
|
2020-09-02 |
2023-04-10 |
Enveric Biosciences Canada Inc |
Derivados nitrados de psilocibina y uso de los mismos para modular el receptor 5-ht2a y para tratar un trastorno psiquiatrico.
|
|
WO2022060763A2
(en)
*
|
2020-09-17 |
2022-03-24 |
Merck Sharp & Dohme Corp. |
Modified imidazopyridines as glucosylceramide synthase inhibitors
|
|
AU2022218921A1
(en)
*
|
2021-02-12 |
2023-09-21 |
Enveric Biosciences Canada Inc. |
Multi-substituent psilocybin derivatives and methods of using
|
|
IL305481A
(en)
*
|
2021-03-02 |
2023-10-01 |
Mindset Pharma Inc |
Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
|
|
US20240254087A1
(en)
*
|
2021-05-11 |
2024-08-01 |
Saint Joseph's University |
Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
|
|
US12378194B2
(en)
|
2021-05-25 |
2025-08-05 |
Atai Therapeutics, Inc. |
N, n-dimethyltryptamine salts and crystalline salt forms
|
|
IL309074A
(en)
|
2021-06-08 |
2024-02-01 |
Entheogenix Biosciences Inc |
Substances for the activation of serotonin receptors
|
|
WO2022261383A1
(en)
|
2021-06-09 |
2022-12-15 |
ATAI Life Sciences AG |
Novel prodrugs and conjugates of dimethyltryptamine
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
EP4457203A4
(en)
|
2021-12-27 |
2025-12-17 |
Atai Therapeutics Inc |
AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
|
|
US12012381B2
(en)
|
2021-12-30 |
2024-06-18 |
Atai Therapeutics, Inc. |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
US11746087B1
(en)
|
2022-03-18 |
2023-09-05 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
WO2024229149A1
(en)
|
2023-05-01 |
2024-11-07 |
Atai Therapeutics Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
US20250243160A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|